ID: h-7094b1202c
Hypothesis
LRRK2 Kinase Inhibition Reduces α-Synuclein Spread via Lysosomal Enhancement
LRRK2 G2019S gain-of-function mutation hyperactivates kinase activity, dysregulating RAB GTPases and impairing lysosomal function, permitting α-synuclein oligomer accumulation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
LRRK2 G2019S gain-of-function mutation hyperactivates kinase activity, dysregulating RAB GTPases and impairing lysosomal function, permitting α-synuclein oligomer accumulation. LRRK2 inhibitors (BIIB122, DNL151) restore lysosomal acidification and clearance. Major barriers include NHP lung toxicity findings requiring reformulation, incomplete penetrance of G2019S in humans, and minimal spontaneous α-synuclein pathology in G2019S knock-in mice without additional stressors.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["LRRK2 G2019S<br/>Gain of Function"]
B["Increased Kinase<br/>Activity"]
C["Rab29 Recruitment<br/>Lysosomal Membrane"]
D["Enhanced Lysosomal<br/>Volume Sensing"]
E["Lysosomal<br/>Dysfunction"]
F["Autophagy<br/>Impairment"]
G["Neuronal<br/>Cell Death"]
H["Therapeutic Window<br/>Kinase Inhibitors"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
B --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Contradicts
NHP toxicology revealed lung pathology requiring dose-limiting modifications
Contradicts
LRRK2 G2019S has incomplete penetrance—many carriers reach old age without PD
Contradicts
LRRK2 G2019S patient-derived neurons do not consistently show lysosomal deficits
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — LRRK2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for LRRK2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LRRK2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0029
Events (7d)
3
Price History
▼10.2%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6J mice receiving stereotactic injection of pre-formed α-synuclein fibrils (PFFs) into the striatum are treated with DNL151 (50 mg/kg/day oral gavage) for 12 weeks, THEN we will observe a ≥35 | Reduced α-synuclein pathology spread (35-50% decrease in pS129 α-synuclein) and decreased inclusion formation in anatomically connected brain regions | — no observation — | pending | 0.70 |
| IF human iPSC-derived neurons harboring LRRK2 G2019S are treated with BIIB122 (100 nM) for 72 hours, THEN we will observe a ≥40% increase in lysosomal acidification (measured by LysoSensor Green DND-1 | Increased lysosomal acidification (pH decrease of ≥0.5 units) and reduced α-synuclein oligomer accumulation by 30-50% | — no observation — | pending | 0.75 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF human iPSC-derived neurons harboring LRRK2 G2019S are treated with BIIB122 (100 nM) for 72 hours, THEN we will observe a ≥40% increase in lysosomal acidification (measured by LysoSensor Green DND-189 ratiometric pH) and a ≥30% reduction in α-synuclein oligomer concentration (measured by α-synucle
Predicted outcome: Increased lysosomal acidification (pH decrease of ≥0.5 units) and reduced α-synuclein oligomer accumulation by 30-50%
Falsification: No statistically significant change in lysosomal pH (p > 0.05) or α-synuclein oligomer levels (p > 0.05) between BIIB122-treated and vehicle-treated G2019S neurons after 72-hour incubation
pendingconf 70%
IF C57BL/6J mice receiving stereotactic injection of pre-formed α-synuclein fibrils (PFFs) into the striatum are treated with DNL151 (50 mg/kg/day oral gavage) for 12 weeks, THEN we will observe a ≥35% reduction in phospho-S129 α-synuclein accumulation (measured by ELISA) and a ≥25% reduction in Thi
Predicted outcome: Reduced α-synuclein pathology spread (35-50% decrease in pS129 α-synuclein) and decreased inclusion formation in anatomically connected brain regions
Falsification: No statistically significant reduction in phospho-S129 α-synuclein levels or Thioflavin T-positive inclusions in DNL151-treated mice compared to vehicle controls (p > 0.05 for both metrics)
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.